Trial Profile
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GMI-1359 in Healthy Adult Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs GMI 1359 (Primary)
- Indications Cancer; Haematological malignancies; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors GlycoMimetics
- 01 Sep 2018 Status changed from active, no longer recruiting to completed, according to results published in the Clinical Pharmacology in Drug Development: 2018 Annual Meeting of the American College of Clinical Pharmacology.
- 01 Sep 2018 Results published in the Clinical Pharmacology in Drug Development: 2018 Annual Meeting of the American College of Clinical Pharmacology.
- 30 May 2018 Planned End Date changed from 1 Oct 2017 to 1 Dec 2018.